Compare ANPA & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANPA | FTRE |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 948.9M | 829.3M |
| IPO Year | N/A | 2023 |
| Metric | ANPA | FTRE |
|---|---|---|
| Price | $8.84 | $9.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $15.39 |
| AVG Volume (30 Days) | 23.7K | ★ 1.2M |
| Earning Date | 02-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,723,400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.01 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $2.80 | $3.97 |
| 52 Week High | $180.64 | $18.67 |
| Indicator | ANPA | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 36.22 | 42.51 |
| Support Level | $8.11 | $8.85 |
| Resistance Level | $9.43 | $11.22 |
| Average True Range (ATR) | 0.73 | 0.62 |
| MACD | 1.64 | 0.16 |
| Stochastic Oscillator | 48.44 | 53.29 |
Rich Sparkle Holdings Ltd is financial printing and corporate services provider which engaged in designing and printing financial print materials in Hong Kong. It service portfolio covers a myriad of deliverables, mainly including listing documents, financial reports, fund documents, circulars and announcements. The company's core business includes (i) financial printing services such as printing, typesetting and translation, (ii) advisory services including Environmental, Social and Governance Report and (iii) other services. Key revenue is generated from Financial printing services.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.